Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Compugen Ltd CGEN

Healthcare Biotechnology
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company's pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company... see more

Recent & Breaking News (NDAQ:CGEN)

Compugen Discloses Successful Validation Results for Novel B7/CD28-like Cancer Immunotherapy Target Candidate

Business Wire October 27, 2014

Compugen Third Quarter 2014 Conference Call Scheduled for Wednesday, October 29, 2014 at 10:00 AM ET

Business Wire October 22, 2014

Compugen Achieves Second Preclinical Milestone in Cancer Immunotherapy Collaboration with Bayer

Business Wire October 14, 2014

Compugen Immune Checkpoint Results Being Presented at Three Scientific Conferences

Business Wire October 6, 2014

Compugen Discloses New Results for Novel Target Candidate for Cancer Immunotherapy

Business Wire October 1, 2014

Compugen Announces Presentations of Results for CGEN-15001 Supporting Immune Tolerance Induction

Business Wire September 29, 2014

Compugen Appoints Mr. Ari Krashin as Chief Financial Officer

Business Wire August 25, 2014

Compugen Reacquires Baize's Financial Interest in Pipeline Product Candidates

Business Wire August 21, 2014

Compugen Ltd. Reports 2nd Quarter 2014 Financial Results

Business Wire August 6, 2014

CORRECTED DATE FOR Q2 CONFERENCE CALL: Compugen Second Quarter 2014 Conference Call Scheduled for Wednesday, August 6, 2014 at 10:00 AM EDT

Business Wire July 31, 2014

Compugen Second Quarter 2014 Conference Call Scheduled for Tuesday, August 5, 2014 at 10:00 AM EDT

Business Wire July 29, 2014

Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences

Business Wire July 24, 2014

Compugen Extends Discovery Capabilities to Additional Immunomodulatory Proteins

Business Wire July 14, 2014

Compugen Discloses Achievement of Milestone in Cancer Immunotherapy Collaboration with Bayer

Business Wire July 7, 2014

Compugen Discloses Experimental Results for Novel Checkpoint Candidate for Cancer Immunotherapy and Discovery of Two New Candidates

Business Wire June 16, 2014

Compugen Ltd. Reports First Quarter 2014 Results

Business Wire May 19, 2014

Compugen Appoints Mr. Avihai Shen Interim CFO

Business Wire May 12, 2014

Compugen First Quarter 2014 Conference Call Scheduled for Monday, May 19, 2014 at 10:00 AM EST

Business Wire May 5, 2014

Compugen to Present at Immunology 2014 Conference

Business Wire April 29, 2014

Compugen Statement Regarding Insider Trading Allegations

Business Wire April 7, 2014